Evidence summaries and landmark trials across type 1, type 2, prevention, glycaemic control, complications, and diabetes technology.
A first-in-human Phase I dose-escalation study found the dual GLP-1/GIP receptor agonist BGM0504 was generally safe and well tolerated in 40 healthy volunteers, with dose-related weight reduction and gastrointestinal adverse events. PICO summary and expert commentary.
A 78-patient randomised placebo-controlled trial of the GLP-1 analogue Ebenatide in type 2 diabetes, with a between-group glycaemic edge at Week 24 only. PICO summary and expert commentary.
COMBINE 2 found once-weekly IcoSema superior to semaglutide 1.0 mg for HbA1c in type 2 diabetes, but body weight significantly favoured semaglutide. PICO summary and expert commentary.
A small single-centre RCT of CGM-guided individualised care versus self-monitoring in 80 women with diabetes in pregnancy, with no between-group glycaemic superiority demonstrated. PICO summary and expert commentary.
Acute empagliflozin produced robust, comparable urinary glucose excretion in HNF1A-MODY and type 2 diabetes during a hyperglycaemic clamp. PICO summary and expert commentary.
A phase 2 substudy found retatrutide produced dose-related reductions in total body fat mass at 36 weeks versus placebo and dulaglutide in type 2 diabetes. PICO summary and expert commentary.
A post-hoc pooled analysis of three phase 3 trials testing tafolecimab 450 mg every four weeks for LDL-C lowering in Chinese adults with type 2 diabetes and hypercholesterolemia. PICO summary and expert commentary.
A small acute mechanistic crossover study testing whether exenatide-glucagon co-infusion raises myocardial glucose uptake and a diastolic strain-rate marker in eight adults with type 2 diabetes. PICO summary and expert commentary.
A 1-year randomised controlled trial of pharmacist-led collaborative care versus standard care in 400 adults with type 2 diabetes, reporting EQ-5D and visual analogue scale quality-of-life gains alongside a larger HbA1c reduction. PICO summary and expert commentary.
A small single-blind RCT testing whether a family-centered empowerment program improves patient-reported illness acceptance and self-management in type 2 diabetes. PICO summary and expert commentary.
Welcome to Hormone Insight. Our mission is to support clinical decision-making with accessible, evidence-based insights from recent studies and trials.
© 2024-2026 Hormone Insight. All rights reserved.
